Would expect the power plant regulations to put all but the dominant metallurgical coal producers out of business in the next few years. Celanese has a process to convert coal and natural gas to ethanol, so maybe that saves a shadow of the coal industry and puts the water-intensive corn and sugar cane ethanol producers out of business instead. As Bob Dylan sang, the times they are a-changin'.
Still buying. Darned if the market doesn't keep seeking my low bids. Institutions still may be exiting what now definitely is a penny stock (which technically it has been since breaking below $5).
I solely am presuming when a company has $25M cash, $1.5B debt, $20M negative quarterly cash flow and asks shareholders to approve a 100% increase in authorized shares, that it intends to issue additional shares. However, as the proxy mentions, shares could be issued in exchange for debt rather than made available in a rights offering or follow-on offering.
Average in if you do. May go lower on actual dilution announcement, but I am accumulating with expectation of selling within a year or two at three to four times today's price. Also positions for more rights to trade if they go the rights offering route again.
Did ah's spread account for VLO spinning off retail operations at the same time TSO was significantly expanding retail operations?
Does not appear to have been Ross, Watsa or Marks unloading shares. Today would have been the deadline for a 13D or 13G, and none are shown on Edgar for Invesco Private Capital, Fairfax Financial Holdings or Oaktree Capital Management.
Brokerage rep called back laughing. Asked if I was aware I had GTC sell orders pending at $1.80, $1.87, $1.92 and $1.95 from my buying spree last week.
That's a euphemism. Vancouver Energy terminal is being put in a nursing home to die like the Keystone XL pipeline. Opposition is too local, too concentrated and too invested in the outcome.
Most compensation plans include fixed cash and at-risk components (cash, stock or both), but the value and proportion of each (i.e., the pay mix) typically is established to be market -competitive for similar positions in companies of comparable stature (i.e. assets, revenue, net income, etc.). The at-risk components may be short-term (cash) or long-term (equity) incentives.
Stock options, restricted stock, phantom stock and stock appreciation rights, collectively known as equity compensation, are common long-term incentives for executives to achieve group and/or individual performance objectives. Key employees (typically managers and professionals) also may be designated as participants in equity compensation plans.
Standard sales compensation components are salary, commission, bonus and sales incentives (typically non-monetary awards, such as trips or gifts).
The strike price of stock options must be set at fair market value according to IRS rules on the date of the grant. Exercise (vesting) dates are determined by a plan schedule intended to secure the recipient's service over time or to promote achievement of certain performance goals or market share price. Expiration dates most commonly are ten years post-grant or upon termination of employment, immediately for non-vested options and within a short period of time thereafter for vested options.
Clarification required. Looked back at jetbpc's message and he just said MU was interesting due to hedge fund positions but did not see it moving until later this year. Suggested this summer may be a good time to start a position.
Congratulations. What do you see ahead for MU? Is it time to go long? jetbpc had suggested looking into it for some summer action. Maybe he will chime in, too.
Yikes! That's enough shares and under such circumstances a major holder surely is involved. Wilder was supposed to purchase his $40M on the open market, but perhaps he made a deal with someone (not necessarily on the board). Guess we may have to wait up to ten days to find out, but such a transaction could explain the last-minute cliff-dive if someone or someone's computer detected it. Donning my houndstooth hat to investigate. Please report if you see something.
Wow, I suspected something like this when the bottom fell out of the share price. Critical loss, Di Russo was the linchpin for all clinical trials. Says he has been at Pfizer since May. CTSO owed us an 8-K within four business days.
The proxy statement also indicates the additional shares could be used to consummate a merger or acquisition as well as to serve as a poison pill. Didn't Wilder say something about having freedom to do whatever it takes to turn around XCO?